Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.97 |
| ▸ | THRB | P10828 | 2/20 | 0.97 |
| ▸ | HPGD | P15428 | 2/20 | 0.97 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.97 |
| ▸ | RECQL | P46063 | 2/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | MAPT | P10636 | 1/20 | 0.97 |
| ▸ | SNCA | P37840 | 1/20 | 0.97 |
| ▸ | BLM | P54132 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.97 |
| ▸ | SENP2 | Q9HC62 | 4/20 | 0.82 |
| ▸ | SENP1 | Q9P0U3 | 4/20 | 0.82 |
| ▸ | SUMO2 | P61956 | 3/20 | 0.82 |
| ▸ | SUMO1 | P63165 | 3/20 | 0.82 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 0.82 |
| ▸ | SLC7A11 | Q9UPY5 | 5/20 | 0.77 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.72 |
| ▸ | GLB1 | P16278 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Congo Red Free Acid SCHEMBL5147845 | 1.00 | APP (0.97) | APPALDH1A1THRBHPGDALOX12 | |
| Congo Red Free Acid SCHEMBL17272057 | 1.00 | APP (0.97) | APPALDH1A1THRBHPGDALOX12 | |
| Congo Red Free Acid SCHEMBL2583894 | 0.99 | APP (1.00) | APPALDH1A1THRBHPGDALOX12 | |
| Congo Red Free Acid SCHEMBL29825625 | 0.99 | APP (1.00) | APPALDH1A1THRBHPGDALOX12 | |
| Congo Red Free Acid SCHEMBL29350758 | 0.99 | APP (1.00) | APPALDH1A1THRBHPGDALOX12 | |
| Congo Red Free Acid SCHEMBL1254806 | 0.99 | APP (1.00) | APPALDH1A1THRBHPGDALOX12 | |
| Congo Red Free Acid SCHEMBL29415044 | 0.97 | APP (0.97) | APPALDH1A1THRBHPGDALOX12 | |
| SCHEMBL14988501 | 0.94 | APP (0.86) | APPALDH1A1THRBHPGDALOX12 | |
| SCHEMBL14988498 | 0.94 | APP (0.86) | APPALDH1A1THRBHPGDALOX12 | |
| SCHEMBL18044243 | 0.92 | APP (0.88) | APPALDH1A1THRBHPGDALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590658-A2 | COMPOSITIONS AND METHODS FOR REMOVAL OR DESTRUCTION OF AMYLOID FIBRIL OR AMYLOID ADHESIN COMPRISING AGGREGATES | Katholieke Universiteit Leuven (BE) | 2013-05-15 | — | — | EP | claimed |
| WO-2012003554-A2 | COMPOSITIONS AND METHODS FOR REMOVAL OR DESTRUCTION OF AMYLOID FIBRIL OR AMYLOID ADHESIN COMPRISING AGGREGATES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-01-12 | — | — | WO | claimed |
| US-6866867-B2 | Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose | J. RETTENMAIER & SOEHNE GMBH + CO. KG (DE) | 2005-03-15 | — | — | US | claimed |
| US-6395303-B1 | Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose | EDWARD MENDELL CO., INC. | 2002-05-28 | — | — | US | claimed |
| US-6106865-A | MIXTURE OF MICROCRYSTALLINE CELLULOSE, COMPRESSIBILITY, SILICA AND SURFACTANTS | EDWARD MENDELL CO., INC. (US) | 2000-08-22 | — | — | US | claimed |
| WO-2023222136-A1 | DEVICE AND SYSTEM FOR DETECTING MISFOLDED PROTEINS IN BIOLOGICAL SAMPLE | 数问生物技术（宣城）有限公司 | 2023-11-23 | — | — | WO | disclosed |
| US-20210015773-A1 | MAGNESIUM COMPOSITIONS AND USES THEREOF FOR NEUROLOGICAL DISORDERS | NEUROCENTRIA, INC. | 2021-01-21 | — | — | US | disclosed |
| EP-2139466-B1 | MAGNESIUM COMPOSITIONS AND USES THEREOF | NEUROCENTRIA INC (US) | 2019-10-23 | — | — | EP | disclosed |
| US-9757414-B2 | Magnesium compositions and uses thereof for neurological disorders | NEUROCENTRIA, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9737563-B2 | Magnesium compositions and uses thereof for neurological disorders | NEUROCENTRIA, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170112875-A1 | MAGNESIUM COMPOSITIONS AND USES THEREOF FOR NEUROLOGICAL DISORDERS | MAGCEUTICS, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170106016-A1 | MAGNESIUM COMPOSITIONS AND USES THEREOF FOR NEUROLOGICAL DISORDERS | MAGCEUTICS, INC. | 2017-04-20 | — | — | US | disclosed |
| US-6866867-B2 | Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose | J. RETTENMAIER & SOEHNE GMBH + CO. KG (DE) | 2005-03-15 | — | — | US | disclosed |
| US-20030219377-A1 | Compounds and methods for diagnosing and treating amyloid-related conditions | PHARMACIA & UPJOHN COMPANY | 2003-11-27 | — | — | US | disclosed |
| US-6589504-B1 | Binding or aggregating fibrils with radiolabeled quinoline-hydrazone compound | PHARMACIA & UPJOHN COMPANY | 2003-07-08 | — | — | US | disclosed |
| US-20030099702-A1 | Pharmaceutical excipient having improved compressibility | PENWEST PHARMACEUTICALS CO. | 2003-05-29 | — | — | US | disclosed |
| US-20020182259-A1 | Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose | J. RETTENMAIER & SOEHNE GMBH + CO. KG (DE) | 2002-12-05 | — | — | US | disclosed |
| US-6395303-B1 | Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose | EDWARD MENDELL CO., INC. | 2002-05-28 | — | — | US | disclosed |
| US-6106865-A | MIXTURE OF MICROCRYSTALLINE CELLULOSE, COMPRESSIBILITY, SILICA AND SURFACTANTS | EDWARD MENDELL CO., INC. (US) | 2000-08-22 | — | — | US | disclosed |
| US-4764302-A | Thickening system for incorporating fluorescent whitening agents | THE CLOROX COMPANY (US) | 1988-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030219377-A1 | Compounds and methods for diagnosing and treating amyloid-related conditions | APP, IAPP, HTT | APP 1/4885ALDH1A1 694/4885THRB 4735/4885 |
| US-20210015773-A1 | MAGNESIUM COMPOSITIONS AND USES THEREOF FOR NEUROLOGICAL DISORDERS | MAPT, PYGB, ACHE | APP 10/4885ALDH1A1 3538/4885THRB 2393/4885 |
| US-20170112875-A1 | MAGNESIUM COMPOSITIONS AND USES THEREOF FOR NEUROLOGICAL DISORDERS | MAPT, PYGB, ACHE | APP 10/4885ALDH1A1 3538/4885THRB 2393/4885 |
| US-20170106016-A1 | MAGNESIUM COMPOSITIONS AND USES THEREOF FOR NEUROLOGICAL DISORDERS | MAPT, PYGB, ACHE | APP 10/4885ALDH1A1 3538/4885THRB 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.